NO20072851L - High dose prolonged release formulation of gepirone - Google Patents

High dose prolonged release formulation of gepirone

Info

Publication number
NO20072851L
NO20072851L NO20072851A NO20072851A NO20072851L NO 20072851 L NO20072851 L NO 20072851L NO 20072851 A NO20072851 A NO 20072851A NO 20072851 A NO20072851 A NO 20072851A NO 20072851 L NO20072851 L NO 20072851L
Authority
NO
Norway
Prior art keywords
gepirone
release formulation
present
high dose
prolonged release
Prior art date
Application number
NO20072851A
Other languages
Norwegian (no)
Inventor
Stephen J Kramer
Louis F Fabre
Original Assignee
Fabre Kramer Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Holdings Inc filed Critical Fabre Kramer Holdings Inc
Publication of NO20072851L publication Critical patent/NO20072851L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår høydosering forlenget frigivelse formulering av gepiron og fremgangsmåte for behandling av tyngre depresjon ved administrering av samme til et subjekt som trenger det. Mer spesifikt angår foreliggende oppfinnelse en høydosering forlenget frigivelse tablettform av gepiron. Foreliggende oppfinnelse angår også en fremgangsmåte for behandling av depresjon hos pattedyr ved å administrere til et subjekt som trenger det en effektiv mengde av høydosering forlenget frigivelse formuleringen av gepiron ifølge foreliggende oppfinnelse.BACKGROUND OF THE INVENTION The present invention relates to high-dose prolonged-release formulation of gepirone and to the method of treating severe depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high dosage extended release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount of high dosage extended release formulation of gepirone of the present invention.

NO20072851A 2004-11-05 2007-06-05 High dose prolonged release formulation of gepirone NO20072851L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/032785 WO2006052227A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Publications (1)

Publication Number Publication Date
NO20072851L true NO20072851L (en) 2007-07-31

Family

ID=36336794

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072851A NO20072851L (en) 2004-11-05 2007-06-05 High dose prolonged release formulation of gepirone

Country Status (11)

Country Link
EP (1) EP1809255A4 (en)
JP (1) JP2008519071A (en)
CN (1) CN101076320A (en)
AU (1) AU2004324868B2 (en)
BR (1) BRPI0419179A (en)
CA (1) CA2585606A1 (en)
EA (1) EA013213B1 (en)
IL (1) IL182792A0 (en)
MX (1) MX2007005368A (en)
NO (1) NO20072851L (en)
WO (1) WO2006052227A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131906A1 (en) * 2013-11-18 2015-05-19 Gnosis Spa ORAL SOLID COMPOSITIONS WITH SLOW RELEASE
RU2713725C1 (en) * 2019-02-08 2020-02-06 Юрий Владимирович Соколов Biologically active additive and method of its application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
RU2003120446A (en) * 2000-12-08 2005-02-20 Акцо Нобель Н.В. (Nl) Акцо Нобель Н.В. (Nl) PHARMACEUTICAL FORM OF HEPIRON FOR ORAL ADMINISTRATION
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Also Published As

Publication number Publication date
EP1809255A1 (en) 2007-07-25
BRPI0419179A (en) 2007-12-18
JP2008519071A (en) 2008-06-05
MX2007005368A (en) 2007-09-11
EA200701010A1 (en) 2007-10-26
IL182792A0 (en) 2007-08-19
AU2004324868A1 (en) 2006-05-18
EA013213B1 (en) 2010-04-30
CN101076320A (en) 2007-11-21
CA2585606A1 (en) 2006-05-18
AU2004324868B2 (en) 2010-04-29
WO2006052227A1 (en) 2006-05-18
EP1809255A4 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
EA200900264A1 (en) COMPOSITIONS OF FLIBANSERIN AND METHOD OF THEIR PREPARATION
NO20061925L (en) Pharmaceutical preparations for the prevention of overdose or abuse
NO20084256L (en) DPP IV inhibitor formulations
MY141025A (en) Dose forms
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
NO20084826L (en) New administration form of racecadotril
RS52110B (en) Dipeptidyl peptidase inhibitors for treating diabetes
UA89220C2 (en) Method for treatment of hiv/aids by administration of solid pharmaceutical dosage formulation comprising a hiv protease inhibitor in fasted state
ECSP17000643A (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and Paracetamol.
EA200970237A1 (en) APPLICATION TENEKTPLAZY FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
NO20050528L (en) Combination of VEGF receptor tyrosine kinase inhibitors for the treatment of cancer
CR8603A (en) HYDROCLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - (4-BROMO-3-METHYL-5-PROPOXI-THIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
DK1501499T3 (en) Transepicutaneous form of administration for the treatment of restless legs syndrome
BRPI0415953B8 (en) controlled release dosage formulation and set of controlled release dosage forms
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
BRPI0412364A (en) solid pharmaceutical composition comprising amisulpride
NO20072851L (en) High dose prolonged release formulation of gepirone
PL1656131T3 (en) Use of betaine for treating intermittent claudication
AR053154A1 (en) METHOD OF TREATMENT AND COMBINATION OF ROFLUMILAST AND AN INTEGRINE INHIBITOR
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
EA200601286A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT
ATE460934T1 (en) PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN
AR040287A1 (en) PLATFORM FOR TRANSDERMAL FORMULATIONS (PFT)
WO2006009602A3 (en) Multiple ppi dosage form
DK1503803T3 (en) Injectable pharmaceutical composition containing ethanol to treat disc prolapse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application